WO2019103098A1 - 薬剤付与器具および薬剤層の形成方法 - Google Patents
薬剤付与器具および薬剤層の形成方法 Download PDFInfo
- Publication number
- WO2019103098A1 WO2019103098A1 PCT/JP2018/043180 JP2018043180W WO2019103098A1 WO 2019103098 A1 WO2019103098 A1 WO 2019103098A1 JP 2018043180 W JP2018043180 W JP 2018043180W WO 2019103098 A1 WO2019103098 A1 WO 2019103098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- balloon
- layer
- delivery device
- sheet
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 199
- 229940079593 drug Drugs 0.000 title claims abstract description 189
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 239000010410 layer Substances 0.000 claims description 90
- 238000012377 drug delivery Methods 0.000 claims description 65
- 239000012790 adhesive layer Substances 0.000 claims description 46
- 239000000853 adhesive Substances 0.000 claims description 32
- 230000001070 adhesive effect Effects 0.000 claims description 32
- 238000010438 heat treatment Methods 0.000 claims description 16
- 230000002093 peripheral effect Effects 0.000 claims description 8
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- -1 polyethylene Polymers 0.000 description 17
- 239000002904 solvent Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 150000003384 small molecules Chemical class 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 230000010339 dilation Effects 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229960002930 sirolimus Drugs 0.000 description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 230000004323 axial length Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 229960005167 everolimus Drugs 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004830 Super Glue Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GKCXXDSWWDWUHS-BYPYZUCNSA-N ethyl (2s)-2-amino-3-hydroxypropanoate Chemical compound CCOC(=O)[C@@H](N)CO GKCXXDSWWDWUHS-BYPYZUCNSA-N 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229920012753 Ethylene Ionomers Polymers 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- JALHGCPDPSNJNY-UHFFFAOYSA-N [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4h-thieno[3,2-c]pyridin-2-yl] acetate;hydron;chloride Chemical compound Cl.C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 JALHGCPDPSNJNY-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229960000288 dabigatran etexilate Drugs 0.000 description 1
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- PSMMNJNZVZZNOI-SJILXJHISA-N edoxaban tosylate hydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 PSMMNJNZVZZNOI-SJILXJHISA-N 0.000 description 1
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229920006173 natural rubber latex Polymers 0.000 description 1
- 239000002698 neuron blocking agent Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960004947 prasugrel hydrochloride Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 1
- 229950005789 sarpogrelate Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 229960002961 ticlopidine hydrochloride Drugs 0.000 description 1
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B1/00—Layered products having a non-planar shape
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B1/00—Layered products having a non-planar shape
- B32B1/08—Tubular products
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
- B32B15/082—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin comprising vinyl resins; comprising acrylic resins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
- B32B15/085—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
- B32B15/09—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin comprising polyesters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/14—Layered products comprising a layer of metal next to a fibrous or filamentary layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B25/00—Layered products comprising a layer of natural or synthetic rubber
- B32B25/04—Layered products comprising a layer of natural or synthetic rubber comprising rubber as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B25/08—Layered products comprising a layer of natural or synthetic rubber comprising rubber as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B25/00—Layered products comprising a layer of natural or synthetic rubber
- B32B25/10—Layered products comprising a layer of natural or synthetic rubber next to a fibrous or filamentary layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B25/00—Layered products comprising a layer of natural or synthetic rubber
- B32B25/16—Layered products comprising a layer of natural or synthetic rubber comprising polydienes homopolymers or poly-halodienes homopolymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B25/00—Layered products comprising a layer of natural or synthetic rubber
- B32B25/20—Layered products comprising a layer of natural or synthetic rubber comprising silicone rubber
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/12—Layered products comprising a layer of synthetic resin next to a fibrous or filamentary layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/302—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising aromatic vinyl (co)polymers, e.g. styrenic (co)polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/304—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising vinyl halide (co)polymers, e.g. PVC, PVDC, PVF, PVDF
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/306—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising vinyl acetate or vinyl alcohol (co)polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/34—Layered products comprising a layer of synthetic resin comprising polyamides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/36—Layered products comprising a layer of synthetic resin comprising polyesters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/40—Layered products comprising a layer of synthetic resin comprising polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/02—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by features of form at particular places, e.g. in edge regions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/26—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layer; characterised by a layer with cavities or internal voids ; characterised by an apertured layer
- B32B3/266—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layer; characterised by a layer with cavities or internal voids ; characterised by an apertured layer characterised by an apertured layer, the apertures going through the whole thickness of the layer, e.g. expanded metal, perforated layer, slit layer regular cells B32B3/12
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/26—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layer; characterised by a layer with cavities or internal voids ; characterised by an apertured layer
- B32B3/30—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layer; characterised by a layer with cavities or internal voids ; characterised by an apertured layer characterised by a layer formed with recesses or projections, e.g. hollows, grooves, protuberances, ribs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
- B32B5/02—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by structural features of a fibrous or filamentary layer
- B32B5/022—Non-woven fabric
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
- B32B7/04—Interconnection of layers
- B32B7/06—Interconnection of layers permitting easy separation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
- B32B7/04—Interconnection of layers
- B32B7/12—Interconnection of layers using interposed adhesives or interposed materials with bonding properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B9/00—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00
- B32B9/02—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising animal or vegetable substances, e.g. cork, bamboo, starch
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B9/00—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00
- B32B9/04—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B9/045—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B9/00—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00
- B32B9/04—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B9/047—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material made of fibres or filaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
- A61M2025/1031—Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1075—Balloon catheters with special features or adapted for special applications having a balloon composed of several layers, e.g. by coating or embedding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/28—Processes for applying liquids or other fluent materials performed by transfer from the surfaces of elements carrying the liquid or other fluent material, e.g. brushes, pads, rollers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/02—Coating on the layer surface on fibrous or filamentary layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/10—Coating on the layer surface on synthetic resin layer or on natural or synthetic rubber layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/26—Polymeric coating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2270/00—Resin or rubber layer containing a blend of at least two different polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2274/00—Thermoplastic elastomer material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/50—Properties of the layers or laminate having particular mechanical properties
- B32B2307/536—Hardness
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/50—Properties of the layers or laminate having particular mechanical properties
- B32B2307/546—Flexural strength; Flexion stiffness
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/728—Hydrophilic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/732—Dimensional properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/732—Dimensional properties
- B32B2307/734—Dimensional stability
- B32B2307/736—Shrinkable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/748—Releasability
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2535/00—Medical equipment, e.g. bandage, prostheses or catheter
Definitions
- the present invention relates to a drug delivery device for placing a drug on the surface of a medical device such as a balloon and a method of forming a drug layer.
- the balloon catheter has been used to improve a lesion (narrowed part) produced in a living body lumen.
- the balloon catheter usually comprises an elongated shaft portion and a radially expandable balloon provided on the distal side of the shaft portion.
- the lesion can be pushed apart by expanding the contracted balloon after reaching a target location in the body via a narrow biological lumen.
- a drug eluting balloon (Drug Eluting Balloon: DEB) coated with a drug for suppressing stenosis on the surface of the balloon has recently been used.
- DEB Drug Eluting Balloon coated with a drug for suppressing stenosis on the surface of the balloon.
- the drug-eluting balloon can be expanded to release the drug coated on the surface to the lesion instantly, thereby suppressing restenosis.
- Patent Document 1 discloses a method of spraying a solution containing a drug onto a balloon, a method of dipping, a method of coating with a brush, a method of coating with a rotating body, a pipette The method of supply etc. are mentioned.
- Patent Document 2 describes a device filled with a drug between a dilation balloon and a drug delivery balloon located outside the dilation balloon.
- the drug delivery balloon is formed with a large number of micropores for releasing the drug, and it is described that an additional drug can be externally delivered between the dilation balloon and the drug delivery balloon.
- Patent Document 1 has difficulty in quickly placing an appropriate amount of drug on the surface of the balloon. Further, the device described in Patent Document 2 can supply the drug from the outside to the balloon, but the structure is complicated, so the drug can not be easily disposed on the balloon.
- the present invention was made to solve the above-mentioned problems, and provides a method for forming a drug delivery device and a drug layer capable of quickly and easily placing an appropriate amount of drug on the surface of a medical device. To aim.
- a drug delivery device for achieving the above object is a drug delivery device which can be applied to a medical device to be used by being inserted into a living body, which comprises a flexible sheet and a drug provided on one side of the sheet. And a layer.
- a method of forming a drug layer according to the present invention for achieving the above object is a method of forming a drug layer for placing a drug on the surface of a medical device to be used by being inserted into a living body, which comprises: And affixing to the surface of the medical device the opposite side of the drug application device on the side on which the drug layer is provided.
- an appropriate amount of the drug layer can be quickly and easily disposed on the surface of the medical device.
- the drug delivery device may further include an adhesive layer provided on the side of the sheet opposite to the side on which the drug layer is provided. Thereby, the adhesive layer is adhered to the surface of the medical device, and the drug layer can be effectively disposed without peeling off the surface of the medical device.
- the sheet may be cylindrical, and the drug layer may be provided on the outer peripheral surface of the sheet.
- an appropriate amount of drug layer can be quickly and easily disposed on the outer peripheral surface of a cylindrical medical device such as a balloon.
- the sheet may be a heat shrinkable tube.
- the diameter of the sheet can be reduced, and the sheet can be placed in close contact with the medical device.
- the adhesive layer may exert adhesion by heating.
- an adhesive layer is also heated and an adhesive layer exhibits adhesive force. Therefore, it is possible to suppress adhesion of the adhesive layer to an unintended position before heating.
- the heat shrinkable tube can be adhered to the appropriate position on the surface of the medical device.
- the medical device may be an expandable and contractible balloon. This allows an appropriate amount of drug layer to be quickly and easily placed on the surface of the balloon.
- the drug of the drug layer may contain at least one selected from the group consisting of rapamycin, paclitaxel, docetaxel, and everolimus. In this way, the drug layer can well suppress restenosis of the stenosis in the blood vessel.
- the drug of the drug layer may contain at least one selected from the group consisting of a water-insoluble drug, a water-soluble drug, and a hydrophilic polymer. In this way, it is possible to apply to the drug layer from various drugs, appropriate drugs tailored to conditions etc. alone or in combination.
- the method for forming a drug layer configured as described above can quickly and easily dispose an appropriate amount of the drug layer on the surface of the medical device by attaching the drug delivery device to the medical device.
- an adhesive layer provided on the opposite side of the sheet on which the drug layer is provided may be adhered to the surface of the medical device.
- the adhesive layer is adhered to the surface of the medical device, and the drug layer can be effectively disposed without peeling off the surface of the medical device.
- the drug delivery device may be attached to a medical device removed from the inside of a living body.
- the drug layer can be disposed on the same medical device and reused.
- the medical device may be an expandable and contractible balloon, a guide wire, a guiding sheath, a guiding catheter or a stent. This allows for the quick and easy placement of the appropriate amount of drug layer on the surface of the balloon, guide wire, guiding sheath, guiding catheter or stent. If the medical device is a balloon, an appropriate amount of drug layer can be quickly and easily placed on the surface of the balloon. Moreover, after removing the balloon used for pre-expansion (pre-expansion) of the target site in the living body, the drug layer can be disposed on the same balloon and reused for post-expansion (post expansion) of the target site.
- pre-expansion pre-expansion
- post expansion post-expansion
- FIG. 5 is a cross-sectional view taken along the line AA of FIG. 4; It is a perspective view which shows the state which is sticking the drug delivery instrument on the balloon. It is sectional drawing which shows the balloon which stuck the drug delivery instrument. It is a perspective view showing the medicine grant instrument concerning a 2nd embodiment.
- FIG. 9 is a cross-sectional view taken along the line BB of FIG. 8; It is a front view which shows the state which covered the chemical
- FIG. 11 is a cross-sectional view taken along the line CC of FIG. It is a front view which shows the balloon which stuck the drug delivery instrument.
- FIG. 13 is a cross-sectional view taken along the line DD of FIG. 12; It is a front view showing the balloon which stuck the medicine grant instrument concerning a 3rd embodiment.
- It is sectional drawing which shows the 1st modification of a drug delivery instrument. It is a front view which shows the modification of a chemical
- the drug applying device 10 is, as shown in FIGS. 1 and 2, a balloon 30 (see FIG. 3) for inserting into and pushing out a narrowed portion of a living body lumen such as a blood vessel. It is a device for placing a layer of drug on the surface to make a drug-eluting balloon.
- medical agent provision apparatus 10 is not limited to the balloon 30, For example, a guide wire, a guiding sheath, a guiding catheter, a stent etc. may be sufficient. In the following, the case where a drug layer is placed on the balloon 30 by the drug delivery device 10 will be exemplified.
- the drug applying device 10 includes a flexible sheet 11, a drug layer 12 containing a drug, and an adhesive layer 13 having adhesion.
- the sheet 11 is a flexible thin film-like member.
- the sheet 11 is preferably thin so that it can be folded with the balloon 30.
- the thickness of the sheet 11 is, for example, 1 to 250 ⁇ m, preferably 5 to 100 ⁇ m, and more preferably 10 to 50 ⁇ m.
- the sheet 11 may be formed with shaped recesses and / or protrusions for folding the balloon 30.
- the shaping is possible by applying a force and heating in a state of being deformed into a predetermined shape.
- the recesses and / or protrusions assist in returning (rewrapping) the balloon 30 to the folded state after the drug delivery device 10 is affixed to the balloon 30 that has been expanded from the folded state (see FIG. 5)
- the constituent material of the sheet 11 is, for example, polyolefin, polyvinyl chloride, polystyrene, polyethylene, polypropylene, polyethylene terephthalate, a fluorine-based polymer, a thermoplastic elastomer, a non-woven fabric or the like.
- the drug layer 12 is provided on one side of the sheet 11.
- the drug contained in the drug layer 12 may be a water soluble drug or a water insoluble drug.
- a water insoluble drug means a drug which is insoluble or poorly soluble in water, and specifically, the solubility in water may be less than 1 mg / mL, further less than 0.1 mg / mL.
- Water insoluble drugs include lipid soluble drugs.
- the amount of drug contained in the drug layer 12 is not particularly limited, but it is contained at a density of 0.1 to 10 ⁇ g / mm 2 , preferably 0.5 to 5 ⁇ g / mm 2 , more preferably 0.5 to 3 .5 contained at a density of 5 ⁇ g / mm 2 .
- the thickness of the drug layer 12 is not particularly limited, but is 0.1 to 100 ⁇ m, preferably 0.5 to 50 ⁇ m, more preferably 0.5 to 10 ⁇ m or 10 to 30 ⁇ m.
- the form of the water-insoluble or water-soluble drug is not particularly limited, and may be, for example, crystalline or non-crystalline.
- water insoluble drugs examples include immunosuppressants, eg, cyclosporins including cyclosporin, immunostimulants such as rapamycin, anticancer agents such as paclitaxel, antivirals or antibacterials, antineoplastic agents, Analgesics and anti-inflammatory agents, antibiotics, anti-epileptic agents, anxiolytics, anti-paralytic agents, antagonists, neuron blocking agents, anti-cholinergic agents and cholinergic agents, anti-muscarinic agents and muscarinic agents, anti-adrenergic agents, Includes antiarrhythmic agents, antihypertensive agents, hormonal agents and nutrients.
- immunosuppressants eg, cyclosporins including cyclosporin, immunostimulants such as rapamycin, anticancer agents such as paclitaxel, antivirals or antibacterials, antineoplastic agents, Analgesics and anti-inflammatory agents, antibiotics, anti-epileptic agents, anxiolytic
- the water insoluble drug is preferably at least one selected from the group consisting of rapamycin, paclitaxel, docetaxel and everolimus.
- rapamycin, paclitaxel, docetaxel and everolimus include their analogs and / or their derivatives as long as they have similar efficacy.
- paclitaxel and docetaxel are in an analog relationship.
- Rapamycin and everolimus are in a derivative relationship. Of these, paclitaxel is more preferred.
- the water-soluble drug may be a drug having a solubility in water of 1 mg / mL or more, preferably 5 mg / mL or more, more preferably 10 mg / mL or more, still more preferably 33 mg / mL or more.
- water-soluble anti-platelet agents include clopidogrel sulfate, ticlopidine hydrochloride, prasugrel hydrochloride, sarpogrelate hydrochloride and the like (note that water-insoluble anti-platelet agents include aspirin, cilostazol, ticagrelor, etc.).
- water-soluble anticoagulant examples include warfarin, edoxaban tosylate hydrate, heparin, dabigatran etexilate methanesulfonate and the like.
- the agent may also be a hydrophilic polymer, and can be wet coated with a hydrophilic polymer (a coating that exhibits lubricity when wetted with water).
- the drug is applied not only to the surface (inner and outer surfaces) of the balloon catheter but also as a hydrophilic polymer to the surface (inner and outer surfaces) of a medical device (for example, a guide wire, guiding sheath, guiding catheter, etc.) inserted into a blood vessel. It may be done.
- the drug layer 12 may contain an additive (excipient).
- the additive includes, for example, a water-soluble low molecular weight compound.
- the molecular weight of the water-soluble low molecular weight compound is 50 to 2,000, preferably 50 to 1,000, more preferably 50 to 500, and still more preferably 50 to 200.
- the water-soluble low molecular weight compound is preferably 10 to 5000 parts by mass, more preferably 50 to 3000 parts by mass, and still more preferably 100 to 1000 parts by mass with respect to 100 parts by mass of the water-insoluble drug.
- Water-soluble low molecular weight compounds are composed of serine ethyl ester, saccharides such as glucose, sugar alcohol such as sorbitol, citric acid ester, polysorbate, polyethylene glycol, urea, water soluble polymer, contrast agent, amino acid ester, short chain mono Glycerol esters of carboxylic acids, pharmaceutically acceptable salts and surfactants, etc., or a mixture of two or more of these can be used.
- the water-soluble low molecular weight compound is characterized by having a hydrophilic group and a hydrophobic group and dissolving in water.
- the water soluble low molecular weight compound is preferably non-swelling or hardly swelling.
- the additive containing the water-soluble low molecular weight compound has the effect of uniformly dispersing the water-insoluble drug on the surface of the sheet 11.
- the additive is preferably not a hydrogel.
- the additive contains the low molecular weight compound and dissolves quickly without swelling when in contact with the aqueous solution. Further, the additive is easily dissolved at the time of expansion of the balloon 30 in the blood vessel, so that the crystal particle of the water-insoluble drug on the surface of the balloon 30 is easily released, and the amount of the drug crystal particle attached to the blood vessel is It has the effect of increasing it.
- the water-soluble low molecular weight compound has a molecular weight of 50 to 2,000 and is soluble in water at least 1 mg / mL, preferably at least 5 mg / mL in water, more preferably at least 10 mg / mL in water, further preferably 33 mg / mL It is preferable to dissolve in water and dissolve in water without swelling.
- the water soluble low molecular weight compound is preferably not a hydrogel.
- the water soluble low molecular weight compound is preferably not a polymer, and more preferably not a water insoluble polymer.
- the water soluble low molecular weight compound is preferably not polyethylene glycol (PEG) and water soluble PEG (eg, polyethylene glycol 200-600).
- the solubility of a substance can be defined as the degree of dissolution within 30 minutes at 20 ° C.
- the solubility of a substance can be defined by the amount of solvent (the amount of water) required to dissolve 1 g (or 1 mL) of solute. If the amount of solvent required to dissolve 1 g of solute is less than 1 mL, the solute is very soluble in the solvent. In this case, the dissolution amount is more than 1000 mg / mL.
- Such substances include, for example, sorbitol, urea, glycerol. When the amount of solvent required to dissolve 1 g of solute is 1 mL or more and less than 10 mL, the solute is easily soluble in the solvent.
- the dissolution amount is more than 100 mg / mL and not more than 1000 mg / mL.
- substances include, for example, polysorbate, amino acid ester, polyethylene glycol 200-600, serine ethyl ester, contrast agent (iopromide), water-soluble polymer.
- the amount of solvent required to dissolve 1 g of solute is 10 mL or more and less than 30 mL, the solute is soluble in the solvent.
- the dissolution amount is more than 33 mg / mL and not more than 100 mg / mL.
- substances include, for example, polyethylene glycol.
- the solute When the amount of solvent required to dissolve 1 g of solute is 30 mL or more and less than 100 mL, the solute is hardly soluble in the solvent. In this case, the dissolution amount is more than 10 mg / mL and not more than 33 mg / mL. When the amount of solvent required to dissolve 1 g of solute is 100 mL or more and less than 1000 mL, the solute is hardly soluble in the solvent. In this case, the dissolution amount is more than 1 mg / mL and 10 mg / mL or less. When the amount of solvent required to dissolve 1 g of the solute is 1000 mL or more and less than 10000 mL, the solute is very poorly soluble in the solvent.
- the dissolution amount is more than 0.1 mg / mL and not more than 1 mg / mL.
- the amount of solvent required to dissolve 1 g of solute is 10000 mL or more, the solute is hardly soluble in the solvent.
- the dissolution amount is 0.1 mg / mL or less.
- Such substances include, for example, fatty acid esters of glycerin.
- Water soluble refers to substances other than "very sparingly soluble" and “almost insoluble” substances. Water soluble specifically refers to "very soluble", “soluble”, “slightly soluble”, and “slightly insoluble” materials. Water soluble preferably refers to "very soluble", “soluble” and “slightly insoluble” materials.
- the adhesive layer 13 is provided on the surface of the sheet 11 opposite to the side on which the drug layer 12 is provided.
- the adhesive layer 13 is a layer adhered to the surface of the balloon 30.
- the thickness of the adhesive layer 13 is not particularly limited, but is 0.01 to 50 ⁇ m, preferably 0.1 to 30 ⁇ m, and more preferably 0.1 to 5 ⁇ m.
- the material constituting the adhesive layer 13 may be water soluble or water insoluble.
- water-soluble adhesives include vinyl chloride resin adhesives, vinyl acetate copolymer resin adhesives, EVA resin adhesives, acrylic resin adhesives, acrylic ester adhesives, styrene-butadiene copolymer It is a latex, a water-based urethane adhesive and the like.
- the adhesive layer 13 is, for example, a pressure-sensitive adhesive that adheres by pressing.
- the pressure sensitive adhesive is, for example, a natural rubber latex based adhesive, a silicone pressure sensitive adhesive, an MG latex based adhesive, an acrylic based adhesive, a silica based adhesive and the like.
- the drug delivery device 10 has a size that can cover the area where the drug of the balloon 30 is placed.
- the drug applying device 10 preferably has a size that can cover the straight portion 31.
- distal side the side to be inserted into the living body lumen of the balloon catheter 50
- proximal side the hand side to be manipulated
- the balloon catheter 50 has an elongated shaft portion 20, a balloon 30 provided at a distal portion of the shaft portion 20, and a hub 26 fixed to the proximal end of the shaft portion 20.
- the shaft portion 20 includes an outer tube 21 which is a tube having an open distal end and a proximal end, and an inner tube 22 which is a tube disposed inside the outer tube 21.
- the inner tube 22 is housed in the hollow interior of the outer tube 21 and the shaft portion 20 has a double tube structure at its distal portion.
- the hollow interior of the inner tube 22 is a guide wire lumen 24 through which a guide wire is inserted.
- an expanded lumen 23 is formed to allow the fluid for expanding the balloon 30 to flow.
- the inner pipe 22 opens to the outside at the side opening 25.
- the inner pipe 22 protrudes further to the distal side than the distal end of the outer pipe 21.
- a distal end which is a separate member may be provided at the distal portion of the inner tube 22.
- the balloon 30 (medical device) is located at a straight portion 31 formed in the central portion in the axial direction, a proximal taper portion 32 located on the proximal side of the straight portion 31, and a distal side of the straight portion 31. And a distal tapered portion 33.
- the straight portion 31 has a cylindrical shape having substantially the same outer diameter when expanded.
- the outer diameter of the proximal tapered portion 32 gradually decreases from the straight portion 31 toward the proximal side.
- the outer diameter of the distal tapered portion 33 gradually decreases from the straight portion 31 toward the distal side.
- the straight portion 31 is a site where a drug is placed by the drug delivery device 10.
- the range in which the drug is disposed by the drug applying device 10 is not limited to the straight portion 31 but may include at least a part of the proximal taper portion 32 and the distal taper portion 33 in addition to the straight portion 31. Good. Alternatively, the range in which the drug is disposed by the drug delivery device 10 may be only a part of the straight portion 31.
- the balloon 30 has a balloon fusion portion 34 located at the proximal end of the proximal taper portion 32 fused to the distal portion of the outer tube 21.
- a balloon fusion-sealed portion 35 located at the distal end of the distal tapered portion 33 is fused to the distal portion of the inner tube 22.
- the method of fixing the balloon 30 to the outer tube 21 and the inner tube 22 is not limited to fusion bonding, and may be, for example, adhesive.
- the inside of the balloon 30 is in communication with the dilation lumen 23.
- the balloon 30 can be expanded by injecting the expansion fluid into the balloon 30 through the expansion lumen 23.
- the expansion fluid may be a gas or a liquid, for example, a gas such as helium gas, CO 2 gas, O 2 gas, N 2 gas, Ar gas, air, mixed gas, or a liquid such as physiological saline or contrast medium Can.
- the balloon 30 has a plurality of vanes 37 shaped to project radially.
- the wings 37 can be folded in the circumferential direction.
- the wing portion 37 is formed by a fold line extending substantially in the axial direction of the balloon 30.
- the length of the wing 37 in the longitudinal direction does not exceed the length of the balloon 30.
- the number of the wing portions 37 is not particularly limited, and is, for example, 1 to 7. However, in the present embodiment, there are three.
- the plurality of wing portions 37 are preferably arranged uniformly in the circumferential direction of the balloon 30, but is not limited thereto.
- the axial length of the balloon 30 is not particularly limited, but is preferably 5 to 500 mm, more preferably 10 to 300 mm, and still more preferably 20 to 200 mm.
- the outer diameter of the balloon 30 when expanded is not particularly limited, but is preferably 1 to 10 mm, more preferably 2 to 8 mm.
- the balloon 30 have a certain degree of flexibility, and be expanded when reaching a blood vessel, a tissue or the like, and have a certain degree of hardness so as to release the drug possessed on the surface thereof.
- it is made of metal or resin.
- at least the surface of the balloon 30 is made of resin.
- the constituent material of at least the surface of the balloon 30 is, for example, polyolefin such as polyethylene, polypropylene, polybutene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, ionomer, or a mixture of two or more of them, soft polychloride
- a thermoplastic resin such as vinyl resin, polyamide, polyamide elastomer, nylon elastomer, polyester, polyester elastomer, polyurethane, fluorine resin, silicone rubber, latex rubber, etc. can be used.
- polyamides are preferably mentioned.
- the hub 26 is formed with a proximal opening 27 which communicates with the expansion lumen 23 of the outer tube 21 and functions as a port for inflow and outflow of the expansion fluid.
- a predetermined amount of expansion fluid is injected from the proximal opening 27 of the hub 26 using an indeflator or a syringe, and the balloon 30 is Pump the expansion fluid inside. This causes the folded balloon 30 to expand.
- the adhesive layer 13 of the drug applying device 10 is pressed against the straight portion 31 of the expanded balloon 30. Thus, the adhesive layer 13 is adhered to the straight portion 31. If the drug delivery device 10 is larger than the straight portion 31, it may be cut into an appropriate size.
- the dilation fluid is sucked from the inside of the balloon 30 through the proximal opening 27 of the hub 26 and discharged.
- the balloon 30 is contracted and folded.
- the balloon 30 can be used as a drug-eluting balloon for dilation of a constriction in a living body lumen such as a blood vessel.
- the drug applying device 10 is the drug applying device 10 that can be attached to the balloon 30 (medical device) used by being inserted into a living body, and the flexible sheet 11 and the sheet And a drug layer 12 provided on one side of the substrate 11.
- the drug delivery device 10 By attaching the drug delivery device 10 configured as described above to the surface of the balloon 30, an appropriate amount of the drug layer 12 can be quickly and easily disposed on the surface of the balloon 30.
- the drug delivery device 10 can be used to cover the balloon 30 after use, for example, at a clinical site, because the drug layer 12 can be disposed quickly and easily on the balloon 30. Therefore, for example, it can be applied to the balloon 30 removed from the living body by using for pre-expansion of the constriction (pre-expansion) to form the balloon 30 for post-expansion (post expansion) having the drug layer 12. Therefore, one balloon 30 can play two roles if a pre-expansion balloon and a post-expansion balloon are needed.
- an appropriate drug delivery device 10 from a plurality of drug delivery devices 10 having different sizes, types of drugs, amounts of drugs, and the like.
- the drug delivery device 10 since the drug delivery device 10 is in the form of a sheet, it can be cut out from a large drug delivery device 10 to an appropriate size according to the diameter and length of the balloon 30, for example, at a clinical site.
- the drug applying device 10 further includes an adhesive layer 13 provided on the surface of the sheet 11 opposite to the side on which the drug layer 12 is provided.
- the adhesive layer 13 can be adhered to the surface of the balloon 30, and an appropriate amount of the drug layer 12 can be effectively disposed without peeling off the surface of the balloon 30.
- the adhesive layer 13 may be water soluble.
- the adhesive layer 13 exhibits good adhesiveness because the balloon 30 contains water. Therefore, the surface of the balloon 30 may be wetted before the balloon 30 is covered with the drug delivery device 10. Moreover, in the case of the balloon 30 removed from the living body after the pre-expansion, the possibility of containing water is high, and the adhesiveness is improved.
- the water insoluble drug of the drug layer 12 contains at least one selected from the group consisting of rapamycin, paclitaxel, docetaxel, and everolimus. Thereby, the drug layer 12 can well suppress restenosis of the constricted portion in the blood vessel.
- the drug of the drug layer 12 may contain at least one selected from the group consisting of water-insoluble drugs, water-soluble drugs, and hydrophilic polymers. In this way, it is possible to apply to the drug layer 12 a variety of drugs, appropriate drugs meeting conditions, etc. alone or in combination.
- the medical device to which the drug delivery device 10 is affixed is a balloon 30 which can be expanded and contracted. Therefore, the drug layer 12 can be quickly and easily disposed on the surface of the balloon 30.
- the present invention also includes a method of forming a drug layer for placing a drug on the surface of the balloon 30.
- the method of forming the drug layer is a method of forming a drug layer for placing a drug on the surface of a balloon 30 (medical device) used by being inserted into a living body, and the drug on one side of the flexible sheet 11 Affixing to the surface of the balloon 30 an opposite surface of the drug delivery device 10 provided with the layer 12 on the side on which the drug layer 12 is provided.
- the method for forming a drug layer configured as described above can attach an appropriate amount of drug to the surface of the balloon 30 quickly and easily by attaching the drug delivery device 10 to the balloon 30.
- an adhesive layer 13 provided on the side opposite to the side on which the drug layer 12 of the sheet 11 is provided may be adhered to the surface of the balloon 30.
- the adhesive layer 13 can be adhered to the surface of the balloon 30, and the drug layer 12 can be effectively disposed without peeling off the surface of the balloon 30.
- the drug applying device 10 may be attached to the balloon 30 removed from the inside of the living body.
- the drug layer 12 can be disposed on the same balloon 30 and reused.
- the medical device to which the drug delivery device 10 is attached is a balloon 30 which can be expanded and contracted. This allows the appropriate amount of drug layer 12 to be quickly and easily placed on the surface of the balloon 30. Moreover, after removing the balloon 30 used for pre-expansion (pre-expansion) of the target site of the living body, the drug layer 12 can be disposed on the same balloon 30 and reused for post-expansion (post expansion) of the target site.
- the drug applying device 60 according to the second embodiment of the present invention differs from the first embodiment in that it is cylindrical as shown in FIGS.
- the parts having the same functions as those in the first embodiment are given the same reference numerals, and the description thereof is omitted.
- the drug applying device 60 includes a heat-shrinkable tube 61 (sheet) which shrinks upon heating, a drug layer 12 containing a drug, and an adhesive layer 13 having adhesion.
- the drug layer 12 is provided on the outer peripheral surface of the heat shrinkable tube 61.
- the adhesive layer 13 is provided on the inner peripheral surface of the heat shrinkable tube 61.
- the heat-shrinkable tube 61 which is a sheet, is a tube whose diameter is reduced by heating.
- the heat-shrinkable tube 61 has a strength capable of maintaining the through hole 62.
- the heat shrinkable tube 61 may be a cylindrical film. Since the cylindrical film is flexible and thin, it does not necessarily have the strength to maintain the through hole 62, and can be deformed into a flat plate so that the through hole 62 is closed.
- the constituent material of the heat-shrinkable tube 61 is not limited as long as the diameter thereof is reduced by heating, but it is preferable that the material can cover the inner peripheral surface with a drug.
- the heat shrinkable tube 61 preferably shrinks at a relatively low heating temperature.
- the temperature at which the heat shrinkable tube 61 shrinks is, for example, 40 to 150 ° C., preferably 40 to 100 ° C.
- the contraction ratio (inner diameter after contraction / inner diameter before contraction) of the heat-shrinkable tube 61 is not particularly limited, but is preferably 40 to 80%.
- the heat-shrinkable tube 61 may be formed with shaped recesses and / or protrusions for folding the balloon 30.
- the shaping is possible by applying a force and heating in a state of being deformed into a predetermined shape.
- the recesses and / or protrusions have a function of assisting the balloon 30 to return to a folded state (rewrap) after the drug delivery device 60 is attached to the expanded balloon 30.
- the constituent material of the tube-shaped heat-shrinkable tube 61 is, for example, polyolefin, fluorine-based polymer, polyvinyl chloride, thermoplastic elastomer or the like.
- the material of the heat-shrinkable tube 61 in the case of a tubular film is, for example, polyolefin, polyvinyl chloride, polystyrene, polyethylene, polypropylene, polyethylene terephthalate or the like.
- the material that constitutes the adhesive layer 13 may be a material that exerts an adhesive force by raising the temperature to a temperature at which the sheet 11 is heated.
- materials that exhibit adhesion by heating include styrene-butadiene rubber adhesives, poly (lactide-co-glycotide) copolymers, polymers such as polycaprolactone, polyethylene glycol, polyoxyethylene fatty acid diester, and polyoxyethylene.
- surfactants such as fatty acid monoesters and polyoxyethylene polyoxypropylene block polymers, ⁇ -cyanoacrylate adhesives used as adhesives for medical use, fibrin adhesives and the like.
- the drug delivery device 60 is used by internally housing the balloon 30 in the expanded state. Therefore, the inner diameter of the drug delivery device 60 is preferably equal to or greater than the outer diameter of the expanded balloon 30.
- the axial length of the drug delivery device 60 is preferably equal to or greater than the axial length of the range in which the drug of the balloon 30 is disposed when heated and contracted. In the present embodiment, the axial length of the drug applying device 60 exceeds the length of the straight portion 31.
- a predetermined amount of expansion fluid is injected from the proximal opening 27 of the hub 26 using an indeflator or a syringe, and the balloon 30 is Pump the expansion fluid inside. This causes the folded balloon 30 to expand, as shown in FIGS. Next, the balloon 30 is inserted into the through hole 62 of the drug delivery device 60. The balloon 30 may be expanded after the balloon 30 is inserted into the through hole 62.
- the drug applying device 60 is heated to a temperature at which the heat-shrinkable tube 61 shrinks by a drier or an oven or the like that supplies hot air by flowing an electric current.
- a drier or an oven or the like that supplies hot air by flowing an electric current.
- the diameter of the heat-shrinkable tube 11 is reduced, and the adhesive layer 13 is in close contact with the balloon 30.
- the adhesive layer 13 is adhered to the surface of the balloon 30.
- the adhesive layer 13 is an adhesive that exerts an adhesive force by heating
- the adhesive layer 13 is also heated when the heat-shrinkable tube 61 is heated, and the adhesive layer 13 is adhered to the surface of the balloon 30.
- the contracted drug delivery device 60 can cover the entire straight portion 31. Furthermore, the distal end of the contracted drug delivery device 60 covers the proximal portion of the distal taper portion 33, and the proximal end of the contracted drug delivery device 60 covers the distal portion of the proximal tapered portion 32. Can. As a result, both ends of the drug applying device 60 are smaller in diameter than the portion covering the straight portion 31 and thermally shrink. As a result, the drug delivery device 60 is firmly fixed to the balloon 30 without detachment. The distal end of the contracted drug delivery device 60 may not cover the proximal portion of the distal tapered portion 33. Also, the proximal end of the contracted drug delivery device 60 may not cover the distal portion of the proximal taper 32.
- the dilation fluid is sucked from the inside of the balloon 30 through the proximal opening 27 of the hub 26 and discharged.
- the balloon 30 is contracted and folded.
- the balloon 30 can be used as a drug-eluting balloon for dilation of a constriction in a living body lumen such as a blood vessel.
- the sheet in the second embodiment is cylindrical, and the drug layer 12 is provided on the outer peripheral surface of the sheet.
- an appropriate amount of the drug layer 12 can be quickly and easily disposed on the outer peripheral surface of the cylindrical medical device such as the balloon 30.
- the sheet of the medicine applying device 60 is a heat shrinkable tube 61.
- the heat-shrinkable tube 61 which is a sheet, can be reduced in diameter and brought into close contact with the balloon 30 by covering the balloon 30 with the medicine application device 60 and heating.
- the adhesive layer 13 may exert adhesion by heating. Thereby, when the heat-shrinkable tube 61 is heated, the adhesive layer 13 is also heated, and the adhesive layer 13 exerts an adhesive force. For this reason, it is possible to suppress adhesion of the adhesive layer 13 to an unintended position before heating. Therefore, after the drug layer 13 is positioned with high accuracy relative to the balloon 30, the heat-shrinkable tube 61 can be adhered to an appropriate position on the surface of the balloon 30.
- the drug applying device 70 according to the third embodiment of the present invention differs from the first embodiment in that it is in the form of a strip-like elongated tape as shown in FIG.
- the parts having the same functions as those in the first embodiment are given the same reference numerals, and the description thereof is omitted.
- the drug applying device 70 has the same structure (sheet 11, drug layer 12, adhesive layer 13) other than the shape as that of the first embodiment.
- the drug delivery device 70 When using the drug delivery device 70, the drug delivery device 70 is cut to a length matched to the size of the balloon 30, spirally wound around the expanded balloon 30, and the adhesive layer 13 is adhered to the balloon 30. Thereby, the drug layer 12 of an appropriate size can be easily disposed for the balloon 30 of any size.
- the balloon catheter 50 may be a rapid exchange type, but may be an over-the-wire type.
- the target on which the drug layer 12 is disposed by the drug delivery device 10, 60, 70 is not limited to the balloon 30 as long as it is a medical device used by being inserted into a living body, for example, a stent, a covered stent, an implant It may be
- the drug delivery device may not be provided with the adhesive layer if it is attached to the surface of the balloon 30.
- an adhesive is attached to the bonding surface of the drug delivery device or the surface of the balloon 30.
- the adhesive is not particularly limited, but is preferably a liquid adhesive.
- a cyanoacrylate-based instant adhesive, a fibrin adhesive, a starch-based adhesive, a natural rubber-based adhesive, a cellulose-based adhesive, a polyamide-based It is an adhesive or the like. This allows the drug delivery device to adhere to the surface of the balloon 30, even if the drug delivery device is not provided with an adhesive layer in advance.
- a protective film 17 which can be peeled off from the adhesive layer 13 may be attached to the adhesive layer 13. Thereby, it can suppress that refuse etc. adhere to the contact bonding layer 13 before use.
- the protective film 17 can be easily peeled off before adhering the adhesive layer 13 to the balloon 30.
- a drug protection film 18 covering the drug layer 12 may be attached to the drug layer 12.
- the drug protective film 18 is peelably attached to the drug layer 12.
- the drug protection film 18 may be a water soluble film. In this case, after the adhesive layer 13 is adhered to the balloon 30, the balloon 30 can be inserted into the blood vessel without removing the drug protective film 18 from the drug layer 12.
- the balloon catheter 50 to which the drug transfer device loaded with the drug protection film 18 is attached can suppress the detachment of the drug when inserted into the blood vessel.
- the constituent material of the drug protective film 18 is, for example, a gelatin film, a collagen film, a starch film or the like.
- the drug protection film 18 may be attached to the drug layer 12 via a biocompatible adhesive.
- the biocompatible adhesive is, for example, a cyanoacrylate adhesive, gelatin adhesive, fibrin adhesive or the like.
- the drug layer 12 may be partially disposed on the surface of the sheet 11 (or the heat-shrinkable tube 61) as in the second modified example shown in FIG. 16 (A).
- the shape of the range in which the drug layer 12 is provided is not particularly limited. Therefore, the drug delivery device 10, 60, 70 can set the range in which the drug layer 12 is provided arbitrarily.
- the drug delivery device 10, 60, 70 may have a plurality of holes 16 as in the third modified example shown in FIG. 16 (B).
- the number and shape of the holes 16 are not particularly limited.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Child & Adolescent Psychology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Mechanical Engineering (AREA)
- Textile Engineering (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
医療器具の表面に、適切な量の薬剤を迅速かつ容易に配置できる薬剤付与器具および薬剤層の形成方法を提供する。 生体内に挿入して使用されるバルーン(30に張り付け可能な薬剤付与器具(10)であって、柔軟なシート(11)と、シート(11)の一方面に設けられる薬剤層(12)と、を有する。
Description
本発明は、バルーン等の医療器具の表面に薬剤を配置するための薬剤付与器具および薬剤層の形成方法に関する。
近年、生体管腔内に生じた病変部(狭窄部)の改善のために、バルーンカテーテルが用いられている。バルーンカテーテルは、通常、長尺なシャフト部と、シャフト部の遠位側に設けられて径方向に拡張可能なバルーンとを備えている。収縮されているバルーンを、細い生体管腔を経由して体内の目的場所まで到達させた後に拡張させることで、病変部を押し広げることができる。
しかしながら、病変部を強制的に押し広げると、平滑筋細胞が過剰に増殖して病変部に新たな狭窄(再狭窄)が発症する場合がある。このため、最近では、バルーンの表面に狭窄を抑制するための薬剤をコーティングした薬剤溶出バルーン(Drug Eluting Balloon:DEB)が用いられている。薬剤溶出バルーンは、拡張することで表面にコーティングされている薬剤を病変部へ瞬時に放出し、これにより、再狭窄を抑制することができる。
バルーンの表面に薬剤の層を形成する方法として、例えば特許文献1には、バルーンに薬剤を含む溶液をスプレーする方法、ディッピングする方法、ブラシにより塗布する方法、回転体により塗布する方法、ピペットにより供給する方法などが挙げられている。
特許文献2には、拡張用バルーンと、拡張用バルーンの外側に位置する薬剤供給用バルーンとの間に、薬剤を充填したデバイスが記載されている。薬剤供給用バルーンには、薬剤を放出するための多数の微細孔が形成されおり、拡張用バルーンと薬剤供給用バルーンの間には、外部から薬剤を追加供給できることが記載されている。
特許文献1に記載の方法は、バルーンの表面に適切な量の薬剤を迅速に配置することが困難である。また、特許文献2に記載のデバイスは、バルーンに薬剤を外部から供給できるが、構造が複雑であるため、バルーンに薬剤を容易に配置できない。
本発明は、上述した課題を解決するためになされたものであり、医療器具の表面に、適切な量の薬剤を迅速かつ容易に配置できる薬剤付与器具および薬剤層の形成方法を提供することを目的とする。
上記目的を達成する本発明に係る薬剤付与器具は、生体内に挿入して使用される医療器具に張り付け可能な薬剤付与器具であって、柔軟なシートと、前記シートの一方面に設けられる薬剤層と、を有する。
上記目的を達成する本発明に係る薬剤層の形成方法は、生体内に挿入して使用される医療器具の表面に薬剤を配置するための薬剤層の形成方法であって、柔軟なシートの一方面に薬剤層が設けられた薬剤付与器具の前記薬剤層が設けられる側の反対面を、前記医療器具の表面に張り付けるステップを有する。
上記のように構成した薬剤付与器具は、医療器具の表面に張り付けることで、医療器具の表面に、適切な量の薬剤層を迅速かつ容易に配置できる。
前記薬剤付与器具は、前記シートの前記薬剤層が設けられる側と反対側の面に設けられる接着層をさらに有してもよい。これにより、接着層を医療器具の表面へ接着して、薬剤層を医療器具の表面へ剥がれることなく効果的に配置できる。
前記シートは、筒状であり、前記薬剤層は、前記シートの外周面に設けられてもよい。これにより、バルーン等の筒状の医療器具の外周面に、適切な量の薬剤層を迅速かつ容易に配置できる。
前記シートは、熱収縮チューブであってもよい。これにより、医療器具に薬剤付与器具を被せて加熱することで、シートを縮径させ、医療器具に密着させて配置できる。
前記接着層は、加熱により接着力を発揮してもよい。これにより、熱収縮チューブを加熱する際に接着層も加熱され、接着層が接着力を発揮する。このため、加熱する前に、接着層が意図しない位置に接着されることを抑制できる。したがって、薬剤層を医療器具に対して高精度に位置決めした後、熱収縮チューブを医療器具の表面の適切な位置に接着できる。
前記医療器具は、拡張および収縮が可能なバルーンであってもよい。これにより、バルーンの表面に、適切な量の薬剤層を迅速かつ容易に配置できる。
前記薬剤層の薬剤は、ラパマイシン、パクリタキセル、ドセタキセル、およびエベロリムスからなる群から選択される少なくとも1つを含有してもよい。これにより、薬剤層により、血管内の狭窄部の再狭窄を良好に抑制できる。
前記薬剤層の薬剤は、水不溶性薬剤、水溶性薬剤、親水性ポリマーからなる群から選択される少なくとも1つを含有してもよい。これにより、多様な薬剤から、条件等に合わせた適切な薬剤を単独で、または組み合わせて薬剤層に適用できる。
上記のように構成した薬剤層の形成方法は、医療器具に薬剤付与器具を張り付けることで、医療器具の表面に、適切な量の薬剤層を迅速かつ容易に配置できる。
前記張り付けるステップにおいて、前記シートの前記薬剤層が設けられる側の反対面に設けられる接着層を前記医療器具の表面に接着させてもよい。これにより、接着層を医療器具の表面へ接着させて、薬剤層を医療器具の表面へ剥がれることなく効果的に配置できる。
前記張り付けるステップにおいて、生体内から抜去した医療器具に前記薬剤付与器具を張り付けてもよい。これにより、生体内で使用した医療器具を生体から抜去した後、同じ医療器具に薬剤層を配置して再利用できる。
前記医療器具は、拡張および収縮が可能なバルーン、ガイドワイヤ、ガイディングシース、ガイディングカテーテルまたはステントであってもよい。これにより、バルーン、ガイドワイヤ、ガイディングシース、ガイディングカテーテルまたはステントの表面に、適切な量の薬剤層を迅速かつ容易に配置できる。医療器具がバルーンであれば、バルーンの表面に、適切な量の薬剤層を迅速かつ容易に配置できる。また、生体内の目的部位の前拡張(プレ拡張)に使用したバルーンを抜去した後、同じバルーンに薬剤層を配置して、目的部位の後拡張(ポスト拡張)に再利用できる。
以下、図面を参照して、本発明の実施の形態を説明する。なお、図面の寸法比率は、説明の都合上、誇張されて実際の比率とは異なる場合がある。
<第1実施形態>
本発明の第1実施形態に係る薬剤付与器具10は、図1、2に示すように、血管等の生体管腔の狭窄部に挿入して押し広げるためのバルーン30(図3を参照)の表面に、薬剤の層を配置し、薬剤溶出型のバルーンとするためのデバイスである。なお、薬剤付与器具10により薬剤の層を配置する医療器具は、バルーン30に限定されず、例えば、ガイドワイヤ、ガイディングシース、ガイディングカテーテル、ステント等であってもよい。以下では、薬剤付与器具10によりバルーン30に薬剤の層を配置する場合を例示する。
本発明の第1実施形態に係る薬剤付与器具10は、図1、2に示すように、血管等の生体管腔の狭窄部に挿入して押し広げるためのバルーン30(図3を参照)の表面に、薬剤の層を配置し、薬剤溶出型のバルーンとするためのデバイスである。なお、薬剤付与器具10により薬剤の層を配置する医療器具は、バルーン30に限定されず、例えば、ガイドワイヤ、ガイディングシース、ガイディングカテーテル、ステント等であってもよい。以下では、薬剤付与器具10によりバルーン30に薬剤の層を配置する場合を例示する。
薬剤付与器具10は、柔軟なシート11と、薬剤を含む薬剤層12と、接着力を有する接着層13とを備えている。
シート11は、柔軟で薄いフィルム状の部材である。シート11は、バルーン30とともに折り畳めるように、薄いことが好ましい。シート11の厚さは、例えば1~250μm、好ましくは5~100μm、より好ましくは10~50μmである。シート11は、バルーン30を折り畳むための形状付けがされた凹部および/または凸部が形成されてもよい。形状付けは、力を作用させて所定の形状に変形させた状態で加熱することで可能である。凹部および/または凸部は、折り畳まれた状態(図5を参照)から拡張したバルーン30に薬剤付与器具10が張り付けられた後、バルーン30を折り畳まれた状態に戻す(リラップする)ことを補助する機能を有する。
シート11の構成材料は、例えばポリオレフィン、ポリ塩化ビニル、ポリスチレン、ポリエチレン、ポリプロピレン、ポリエチレンテレフタレート、フッ素系ポリマー、熱可塑性エラストマー、不織布等である。
薬剤層12は、シート11の一方面に設けられる。薬剤層12に含まれる薬剤は、水溶性薬剤であってもよく、水不溶性薬剤であってもよい。水不溶性薬剤とは、水に不溶または難溶性である薬剤を意味し、具体的には、水に対する溶解度は、1mg/mL未満、さらに、0.1mg/mL未満でもよい。水不溶性薬剤は脂溶性薬剤を含む。薬剤層12に含まれる薬剤量は、特に限定されないが、0.1~10μg/mm2の密度で含まれ、好ましくは0.5~5μg/mm2の密度、より好ましくは0.5~3.5μg/mm2の密度で含まれる。薬剤層12の厚さは、特に限定されないが、0.1~100μmであり、好ましくは0.5~50μm、より好ましくは0.5~10μm若しくは10~30μmである。水不溶性または水溶性である薬剤の形態は、特に限定されず、例えば結晶であっても、結晶でなくてもよい。
いくつかの好ましい水不溶性薬剤の例は、免疫抑制剤、例えば、シクロスポリンを含むシクロスポリン類、ラパマイシン等の免疫活性剤、パクリタキセル等の抗がん剤、抗ウイルス剤または抗菌剤、抗新生組織剤、鎮痛剤および抗炎症剤、抗生物質、抗てんかん剤、不安緩解剤、抗麻痺剤、拮抗剤、ニューロンブロック剤、抗コリン作動剤およびコリン作動剤、抗ムスカリン剤およびムスカリン剤、抗アドレナリン作用剤、抗不整脈剤、抗高血圧剤、ホルモン剤ならびに栄養剤を含む。
水不溶性薬剤は、ラパマイシン、パクリタキセル、ドセタキセル、エベロリムスからなる群から選択される少なくとも1つが好ましい。本明細書においてラパマイシン、パクリタキセル、ドセタキセル、エベロリムスとは、同様の薬効を有する限りそれらの類似体および/またはそれらの誘導体を含む。例えば、パクリタキセルとドセタキセルは類似体の関係にある。ラパマイシンとエベロリムスは誘導体の関係にある。これらのうちでは、パクリタキセルがさらに好ましい。
水溶性薬剤は、水に対する溶解度が1mg/mL以上、好ましくは5mg/mL以上、より好ましくは10mg/mL以上、さらに好ましくは33mg/mL以上の薬剤であればよい。水溶性の抗血小板薬としては、クロピドグレル硫酸塩、チクロピジン塩酸塩、プラスグレル塩酸塩、サルポグレラート塩酸塩などである(なお、水不溶性の抗血小板薬は、アスピリン、シロスタゾール、チカグレロルなどがある)。水溶性の血液凝固阻止剤としては、ワルファリン、エドキサバントシル酸塩水和物、ヘパリン、ダビガトランエテキシラートメタンスルホン酸塩等が挙げられる。薬剤はまた、親水性ポリマーであってもよく、親水性ポリマーによる湿潤コーティング(水に濡れると潤滑性を発揮するコーティング)が可能である。薬剤は、バルーンカテーテルの表面(内外表面)に限らず、血管内に挿入する医療機器(例えば、ガイドワイヤ、ガイディングシース、ガイディングカテーテル等)の表面(内外表面)に、親水性ポリマーとして適用されてもよい。
薬剤層12は、添加剤(賦形剤)を含んでもよい。薬剤層12に添加剤が含まれる場合、添加剤は、例えば、水溶性の低分子化合物を含む。水溶性の低分子化合物の分子量は、50~2000であり、好ましくは50~1000であり、より好ましくは50~500であり、さらに好ましくは50~200である。水溶性の低分子化合物は、水不溶性薬剤100質量部に対して、好ましくは10~5000質量部、より好ましくは50~3000質量部、さらに好ましくは100~1000質量部である。水溶性の低分子化合物の構成材料は、セリンエチルエステル、グルコースなどの糖類、ソルビトールなどの糖アルコール、クエン酸エステル、ポリソルベート、ポリエチレングリコール、尿素、水溶性ポリマー、造影剤、アミノ酸エステル、短鎖モノカルボン酸のグリセロールエステル、医薬として許容される塩および界面活性剤等、あるいはこれら二種以上の混合物等が使用できる。水溶性の低分子化合物は、親水基と疎水基を有し、水に溶解することを特徴とする。水溶性の低分子化合物は、非膨潤性または難膨潤性であることが好ましい。水溶性の低分子化合物を含む添加剤は、シート11の表面上で水不溶性薬剤を均一に分散させる効果を有する。添加剤は、ハイドロゲルでないことが好ましい。添加剤は低分子化合物を含有することで、水溶液に接すると膨潤することなく速やかに溶解する。さらに、血管内でのバルーン30の拡張時に添加剤が溶解しやすくなることで、バルーン30の表面上の水不溶性薬剤の結晶粒子を放出しやすくなり、血管への薬剤の結晶粒子の付着量を増加させる効果を有する。
水溶性低分子化合物は、分子量が50~2000であって1mg/mL以上水に溶け、好ましくは5mg/mL以上水に溶け、さらに好ましくは10mg/mL以上水に溶け、さらに好ましくは33mg/mL以上水に溶け、膨潤せずに水に溶解することが好ましい。水溶性低分子化合物は、ハイドロゲルではないことが好ましい。水溶性低分子化合物は、ポリマーではないことが好ましく、さらには水不溶性ポリマーではないことが好ましい。水溶性低分子化合物は、ポリエチレングリコール(PEG)および水溶性PEG(たとえば、ポリエチレングリコール200-600)ではないことが好ましい。
物質の溶解性は、20℃で30分以内に溶ける度合いで定義できる。例えば、物質の溶解性は、溶質1g(又は1mL)を溶かすのに要する溶媒量(水の量)で定義できる。溶質1gを溶かすのに要する溶媒量が1mL未満である場合、溶質は溶媒に極めて溶けやすい。この場合、溶解量は1000mg/mL超である。このような物質は、例えばソルビトール、尿素、グリセロールが挙げられる。溶質1gを溶かすのに要する溶媒量が1mL以上10mL未満である場合、溶質は溶媒に溶けやすい。この場合、溶解量は100mg/mLを超えて1000mg/mL以下である。このような物質は、例えばポリソルベート、アミノ酸エステル、ポリエチレングリコール200-600、セリンエチルエステル、造影剤(イオプロミド)、水溶性ポリマーが挙げられる。溶質1gを溶かすのに要する溶媒量が10mL以上30mL未満である場合、溶質は溶媒にやや溶けやすい。この場合、溶解量は33mg/mLを超えて100mg/mL以下である。このような物質は、例えばポリエチレングリコールが挙げられる。溶質1gを溶かすのに要する溶媒量が30mL以上100mL未満である場合、溶質は溶媒にやや溶けにくい。この場合、溶解量は10mg/mLを超えて33mg/mL以下である。溶質1gを溶かすのに要する溶媒量が100mL以上1000mL未満である場合、溶質は溶媒に溶けにくい。この場合、溶解量は1mg/mLを超えて10mg/mL以下である。溶質1gを溶かすのに要する溶媒量が1000mL以上10000mL未満である場合、溶質は溶媒に極めて溶けにくい。この場合、溶解量は0.1mg/mLを超えて1mg/mL以下である。溶質1gを溶かすのに要する溶媒量が10000mL以上である場合、溶質は溶媒にほとんど溶けない。この場合、溶解量は0.1mg/mL以下である。このような物質は、例えばグリセリンの脂肪酸エステルが挙げられる。水溶性とは、「極めて溶けにくい」および「ほとんど溶けない」物質以外の物質をいう。水溶性とは、具体的には「極めて溶けやすい」、「溶けやすい」、「やや溶けにくい」、および「溶けにくい」物質を指す。水溶性とは、好ましくは「極めて溶けやすい」、「溶けやすい」および「やや溶けにくい」物質を指す。
接着層13は、シート11の薬剤層12が設けられる側の反対側の面に設けられる。接着層13は、バルーン30の表面に接着される層である。接着層13の厚さは、特に限定されないが、0.01~50μmであり、好ましくは0.1~30μm、より好ましくは0.1~5μmである。
接着層13を構成する材料は、水溶性であっても、水不溶性であってもよい。水溶性の接着剤は、例えば、塩化ビニル樹脂系接着剤、酢酸ビニル共重合樹脂系接着剤、EVA樹脂系接着剤、アクリル樹脂系接着剤、アクリル酸エステル系接着剤、スチレン・ブタジエン共重合体ラテックス、水性ウレタン系接着剤等である。接着層13は、例えば、押し付けることで接着する感圧接着剤である。感圧接着剤は、例えば、天然ゴムラテックス系接着剤、シリコーン感圧接着剤、MGラテックス系接着剤、アクリル系接着剤、シリカ系接着剤等である。
薬剤付与器具10は、バルーン30の薬剤を配置する範囲を覆うことができる大きさを有することが好ましい。例えば、バルーン30のストレート部31に薬剤を配置する場合、薬剤付与器具10は、ストレート部31を覆うことができる大きさを有することが好ましい。
次に、薬剤付与器具10を用いて薬剤を配置するバルーンカテーテル50について、図3~5を参照しつつ説明する。なお、本明細書では、バルーンカテーテル50の生体管腔に挿入する側を「遠位側」、操作する手元側を「近位側」と称することとする。
バルーンカテーテル50は、長尺なシャフト部20と、シャフト部20の遠位部に設けられるバルーン30と、シャフト部20の近位端に固着されたハブ26とを有している。
シャフト部20は、遠位端および近位端が開口した管体である外管21と、外管21の内部に配置される管体である内管22とを備えている。内管22は、外管21の中空内部に納められており、シャフト部20は、遠位部において二重管構造となっている。内管22の中空内部は、ガイドワイヤを挿通させるガイドワイヤルーメン24である。また、外管21の中空内部であって、内管22の外側には、バルーン30の拡張用流体を流通させる拡張ルーメン23が形成される。内管22は、側面開口部25において外部に開口している。内管22は、外管21の遠位端よりもさらに遠位側まで突出している。内管22の遠位部に、別部材である先端チップが設けられてもよい。
バルーン30(医療器具)は、軸心方向における中央部に形成されるストレート部31と、ストレート部31の近位側に位置する近位テーパ部32と、ストレート部31の遠位側に位置する遠位テーパ部33とを備えている。ストレート部31は、拡張させた際に外径が略等しい円筒状となる。近位テーパ部32は、ストレート部31から近位側へ向かって外径が徐々に減少している。遠位テーパ部33は、ストレート部31から遠位側へ向かって外径が徐々に減少している。
ストレート部31は、薬剤付与器具10により、薬剤が配置される部位である。なお、薬剤付与器具10によって薬剤が配置される範囲は、ストレート部31のみに限定されず、ストレート部31に加えて近位テーパ部32や遠位テーパ部33の少なくとも一部が含まれてもよい。または、薬剤付与器具10によって薬剤が配置される範囲は、ストレート部31の一部のみであってもよい。
バルーン30は、近位テーパ部32の近位端に位置するバルーン融着部34が外管21の遠位部に融着されている。また、バルーン30は、遠位テーパ部33の遠位端に位置するバルーン融着部35が内管22の遠位部に融着されている。なお、バルーン30を、外管21および内管22に固定する方法は、融着に限定されず、例えば接着されてもよい。これにより、バルーン30の内部が拡張ルーメン23と連通している。拡張ルーメン23を介してバルーン30に拡張用流体を注入することで、バルーン30を拡張させることができる。拡張用流体は気体でも液体でもよく、例えばヘリウムガス、CO2ガス、O2ガス、N2ガス、Arガス、空気、混合ガス等の気体や、生理食塩水、造影剤等の液体を用いることができる。
バルーン30は、径方向へ突出するように形状付けられた複数の羽根部37を有している。羽根部37は、周方向に寝かせて畳むことができる。羽根部37は、バルーン30の略軸心方向に延びる折り目によって形成される。羽根部37の長軸方向の長さは、バルーン30の長さを超えない。羽根部37の数は特に限定されず、例えば1~7枚であるが、本実施形態では3枚である。複数の羽根部37は、バルーン30の周方向に均一に配置されることが好ましいが、これに限定されない。
バルーン30の軸心方向の長さは特に限定されないが、好ましくは5~500mm、より好ましくは10~300mm、さらに好ましくは20~200mmである。バルーン30の拡張時の外径は、特に限定されないが、好ましくは1~10mm、より好ましくは2~8mmである。
バルーン30は、ある程度の柔軟性を有するとともに、血管や組織等に到達した際に拡張されて、その表面に有する薬剤を放出できるようにある程度の硬度を有するものが好ましい。具体的には、金属や、樹脂で構成される。バルーン30の少なくとも表面は、樹脂で構成されていることが好ましい。バルーン30の少なくとも表面の構成材料は、例えば、ポリエチレン、ポリプロピレン、ポリブテン、エチレン-プロピレン共重合体、エチレン-酢酸ビニル共重合体、アイオノマー、あるいはこれら二種以上の混合物等のポリオレフィンや、軟質ポリ塩化ビニル樹脂、ポリアミド、ポリアミドエラストマー、ナイロンエラストマー、ポリエステル、ポリエステルエラストマー、ポリウレタン、フッ素樹脂等の熱可塑性樹脂、シリコーンゴム、ラテックスゴム等が使用できる。そのなかでも、好適にはポリアミド類が挙げられる。
ハブ26は、外管21の拡張ルーメン23と連通して拡張用流体を流入出させるポートとして機能する近位開口部27が形成されている。
次に、本実施形態に係る薬剤付与器具10の作用を説明する。
薬剤付与器具10によりバルーン30に薬剤を配置する際には、ハブ26の近位開口部27より、インデフレーターまたはシリンジ等を用いて拡張用流体を所定量注入し、拡張ルーメン23を通じてバルーン30の内部に拡張用流体を送り込む。これにより、折り畳まれたバルーン30が拡張する。次に、図6、7に示すように、拡張したバルーン30のストレート部31に、薬剤付与器具10の接着層13を押し付ける。これにより、接着層13が、ストレート部31に接着される。薬剤付与器具10は、ストレート部31よりも大きい場合、適切な大きさに切断してもよい。
次に、バルーン30の内部から、拡張用流体をハブ26の近位開口部27より吸引して排出する。これにより、バルーン30が収縮して折り畳まれた状態となる。これにより、バルーン30を、薬剤溶出型のバルーンとして、血管等の生体管腔内の狭窄部の拡張に利用できる。
以上のように、本実施形態に係る薬剤付与器具10は、生体内に挿入して使用されるバルーン30(医療器具)に張り付け可能な薬剤付与器具10であって、柔軟なシート11と、シート11の一方面に設けられる薬剤層12と、を有する。
上記のように構成した薬剤付与器具10は、バルーン30の表面に張り付けることで、バルーン30の表面に、適切な量の薬剤層12を迅速かつ容易に配置できる。薬剤付与器具10は、バルーン30に薬剤層12を迅速かつ容易に配置できるため、使用の場所を選ばず、例えば臨床現場において、使用後のバルーン30に被せて使用することもできる。このため、例えば、狭窄部の前拡張(プレ拡張)に使用して生体から抜去したバルーン30に適用して、薬剤層12を有する後拡張(ポスト拡張)用のバルーン30とすることができる。したがって、前拡張用のバルーンと後拡張用のバルーンが必要である場合に、1つのバルーン30で2つの役割を果たすことが可能となる。また、例えば大きさ、薬剤の種類、薬剤の量等の異なる複数の薬剤付与器具10から、適切な薬剤付与器具10を適宜選択して使用することもできる。また、薬剤付与器具10は、シート状であるため、例えば臨床現場において、大きな薬剤付与器具10から、バルーン30の径や長さに合わせて、適切な大きさに切り出して使用することもできる。
薬剤付与器具10は、シート11の薬剤層12が設けられる側と反対側の面に設けられる接着層13をさらに有する。これにより、接着層13をバルーン30の表面へ接着して、適切な量の薬剤層12をバルーン30の表面へ剥がれることなく効果的に配置できる。
また、接着層13は水溶性であってもよい。これにより、接着層13は、バルーン30が水分を含んでいることで、良好な接着性を発揮する。このため、バルーン30に薬剤付与器具10を被せる前に、バルーン30の表面を濡らしてもよい。また、前拡張の後に生体から抜去したバルーン30であれば、水分を含んでいる可能性が高く、接着性が向上する。
薬剤層12の水不溶性薬剤は、ラパマイシン、パクリタキセル、ドセタキセル、およびエベロリムスからなる群から選択される少なくとも1つを含有する。これにより、薬剤層12により、血管内の狭窄部の再狭窄を良好に抑制できる。
薬剤層12の薬剤は、水不溶性薬剤、水溶性薬剤、親水性ポリマーからなる群から選択される少なくとも1つを含有してもよい。これにより、多様な薬剤から、条件等に合わせた適切な薬剤を単独で、または組み合わせて薬剤層12に適用できる。
薬剤付与器具10を張り付ける医療器具は、拡張および収縮が可能なバルーン30である。このため、バルーン30の表面に、薬剤層12を迅速かつ容易に配置できる。
また、本発明は、バルーン30の表面に薬剤を配置するための薬剤層の形成方法をも含む。当該薬剤層の形成方法は、生体内に挿入して使用されるバルーン30(医療器具)の表面に薬剤を配置するための薬剤層の形成方法であって、柔軟なシート11の一方面に薬剤層12が設けられた薬剤付与器具10の薬剤層12が設けられる側の反対面を、バルーン30の表面に張り付けるステップを有する。
上記のように構成した薬剤層の形成方法は、バルーン30に薬剤付与器具10を張り付けることで、バルーン30の表面に、適切な量の薬剤を迅速かつ容易に配置できる。
前記張り付けるステップにおいて、シート11の薬剤層12が設けられる側の反対面に設けられる接着層13をバルーン30の表面に接着させてもよい。これにより、接着層13をバルーン30の表面へ接着して、薬剤層12をバルーン30の表面へ剥がれることなく効果的に配置できる。
前記張り付けるステップにおいて、生体内から抜去したバルーン30に薬剤付与器具10を張り付けてもよい。これにより、生体内で使用したバルーン30を生体から抜去した後、同じバルーン30に薬剤層12を配置して再利用できる。
薬剤付与器具10が貼り付けられる医療器具は、拡張および収縮が可能なバルーン30である。これにより、バルーン30の表面に、適切な量の薬剤層12を迅速かつ容易に配置できる。また、生体の目的部位の前拡張(プレ拡張)に使用したバルーン30を抜去した後、同じバルーン30に薬剤層12を配置して、目的部位の後拡張(ポスト拡張)に再利用できる。
<第2実施形態>
本発明の第2実施形態に係る薬剤付与器具60は、図8、9に示すように、筒状である点で、第1実施形態と異なる。なお、第1実施形態と同様の機能を有する部位には、同一の符号を付し、説明を省略する。
本発明の第2実施形態に係る薬剤付与器具60は、図8、9に示すように、筒状である点で、第1実施形態と異なる。なお、第1実施形態と同様の機能を有する部位には、同一の符号を付し、説明を省略する。
薬剤付与器具60は、加熱することで収縮する熱収縮チューブ61(シート)と、薬剤を含む薬剤層12と、接着力を有する接着層13とを備えている。薬剤層12は、熱収縮チューブ61の外周面に設けられる。接着層13は、熱収縮チューブ61の内周面に設けられる。
シートである熱収縮チューブ61は、加熱することで縮径するチューブである。熱収縮チューブ61は、貫通孔62を維持できる強度を備えている。なお、熱収縮チューブ61は、筒状のフィルムであってもよい。筒状のフィルムは、柔軟かつ薄いため、貫通孔62を維持できる強度を備えるとは限らず、貫通孔62が塞がるように平板状に変形可能である。
熱収縮チューブ61の構成材料は、加熱することで縮径すれば限定されないが、内周面に薬剤を被覆できる材料であることが好ましい。熱収縮チューブ61は、比較的低温の加熱温度で収縮することが好ましい。熱収縮チューブ61が収縮する温度は、例えば40~150℃、好ましくは40~100℃である。熱収縮チューブ61が、比較的低温で収縮することで、薬剤の変質やバルーン30の変形等を抑制できる。熱収縮チューブ61の内径の収縮率(収縮後の内径/収縮前の内径)は、特に限定さないが、好ましくは40~80%である。熱収縮チューブ61は、バルーン30を折り畳むための形状付けがされた凹部および/または凸部が形成されてもよい。形状付けは、力を作用させて所定の形状に変形させた状態で加熱することで可能である。凹部および/または凸部は、拡張したバルーン30に薬剤付与器具60が張り付けられた後、バルーン30を折り畳まれた状態に戻す(リラップする)ことを補助する機能を有する。
チューブ状の熱収縮チューブ61の構成材料は、例えばポリオレフィン、フッ素系ポリマー、ポリ塩化ビニル、熱可塑性エラストマー等である。
筒状のフィルムである場合の熱収縮チューブ61の構成材料は、例えばポリオレフィン、ポリ塩化ビニル、ポリスチレン、ポリエチレン、ポリプロピレン、ポリエチレンテレフタレート等である。
接着層13を構成する材料は、シート11を加熱する温度に昇温することで接着力を発揮する材料であってもよい。加熱により接着力を発揮する材料は、例えばスチレン-ブタジエンゴム系接着剤、ポリ(ラクチド-co-グリコチド)共重合体、ポリカプロラクトンなどのポリマーや、ポリエチレングリコール、ポリオキシエチレン脂肪酸ジエステルやポリオキシエチレン脂肪酸モノエステル、ポリオキシエチレンポリオキシプロピレンブロックポリマーなどの界面活性剤、医療用の接着剤として使用されているα-シアノアクリレート系接着剤、フィブリン系接着剤等である。
薬剤付与器具60は、拡張した状態のバルーン30を内部に収容して使用される。したがって、薬剤付与器具60の内径は、拡張したバルーン30の外径以上であることが好ましい。
薬剤付与器具60の軸方向の長さは、加熱して収縮した際に、バルーン30の薬剤が配置される範囲の軸方向の長さ以上であることが好ましい。本実施形態では、薬剤付与器具60の軸方向の長さは、ストレート部31の長さを超える。
次に、第2実施形態に係る薬剤付与器具60の作用を説明する。
薬剤付与器具60によりバルーン30に薬剤を配置する際には、ハブ26の近位開口部27より、インデフレーターまたはシリンジ等を用いて拡張用流体を所定量注入し、拡張ルーメン23を通じてバルーン30の内部に拡張用流体を送り込む。これにより、図10、11に示すように、折り畳まれたバルーン30が拡張する。次に、薬剤付与器具60の貫通孔62に、バルーン30を挿入する。なお、貫通孔62にバルーン30を挿入した後に、バルーン30を拡張させてもよい。
次に、薬剤付与器具60を、電流が流れることで熱風を供給するドレイヤーやオーブン等により、熱収縮チューブ61が収縮する温度へ加熱する。これにより、図12、13に示すように、熱収縮チューブ11が縮径し、接着層13がバルーン30に密着する。これにより、接着層13がバルーン30の表面に接着される。接着層13が加熱により接着力を発揮する接着剤である場合、熱収縮チューブ61を加熱する際に接着層13も加熱され、接着層13がバルーン30の表面に接着される。収縮した薬剤付与器具60の軸方向の長さが、ストレート部31の長さを超えていれば、収縮した薬剤付与器具60は、ストレート部31の全体を覆うことができる。さらに、収縮した薬剤付与器具60の遠位端は、遠位テーパ部33の近位部を覆い、収縮した薬剤付与器具60の近位端は、近位テーパ部32の遠位部を覆うことができる。これにより、薬剤付与器具60の両端は、ストレート部31を覆う部位よりも径が小さく熱収縮する。これにより、薬剤付与器具60は、バルーン30に対して外れ難く強固に固定される。なお、収縮した薬剤付与器具60の遠位端は、遠位テーパ部33の近位部を覆わなくてもよい。また、収縮した薬剤付与器具60の近位端は、近位テーパ部32の遠位部を覆わなくてもよい。
次に、バルーン30の内部から、拡張用流体をハブ26の近位開口部27より吸引して排出する。これにより、バルーン30が収縮して折り畳まれた状態となる。これにより、バルーン30を、薬剤溶出型のバルーンとして、血管等の生体管腔内の狭窄部の拡張に利用できる。
以上のように、第2実施形態におけるシートは筒状であり、薬剤層12は、シートの外周面に設けられる。これにより、バルーン30等の筒状の医療器具の外周面に、適切な量の薬剤層12を迅速かつ容易に配置できる。
また、薬剤付与器具60のシートは、熱収縮チューブ61である。これにより、バルーン30に薬剤付与器具60を被せて加熱することで、シートである熱収縮チューブ61を縮径させ、バルーン30に密着させることができる。
接着層13は、加熱により接着力を発揮してもよい。これにより、熱収縮チューブ61を加熱する際に接着層13も加熱され、接着層13が接着力を発揮する。このため、加熱する前に、接着層13が意図しない位置に接着されることを抑制できる。したがって、薬剤層13をバルーン30に対して高精度に位置決めした後、熱収縮チューブ61をバルーン30の表面の適切な位置に接着できる。
<第3実施形態>
本発明の第3実施形態に係る薬剤付与器具70は、図14に示すように、帯状の長尺なテープ状である点で、第1実施形態と異なる。なお、第1実施形態と同様の機能を有する部位には、同一の符号を付し、説明を省略する。薬剤付与器具70は、形状以外の構造(シート11、薬剤層12、接着層13)は、第1実施形態と同様である。
本発明の第3実施形態に係る薬剤付与器具70は、図14に示すように、帯状の長尺なテープ状である点で、第1実施形態と異なる。なお、第1実施形態と同様の機能を有する部位には、同一の符号を付し、説明を省略する。薬剤付与器具70は、形状以外の構造(シート11、薬剤層12、接着層13)は、第1実施形態と同様である。
薬剤付与器具70を使用する際には、薬剤付与器具70を、バルーン30の大きさに合わせた長さに切り、拡張したバルーン30に螺旋状に巻き付け、接着層13をバルーン30に接着させる。これにより、任意の大きさのバルーン30に対して、適切な大きさの薬剤層12を容易に配置できる。
なお、本発明は、上述した実施形態のみに限定されるものではなく、本発明の技術的思想内において当業者により種々変更が可能である。例えば、バルーンカテーテル50は、ラピッドエクスチェンジ型(Rapid exchange type)であるが、オーバーザワイヤ型(Over-the-wire type)であってもよい。
また、薬剤付与器具10、60、70により薬剤層12を配置する対象は、生体内に挿入して使用される医療器具であれば、バルーン30に限定されず、例えばステント、カバードステント、インプラント等であってもよい。
また、薬剤付与器具は、バルーン30の表面に張り付けられるのであれば、接着層を設けられなくてもよい。この場合、薬剤付与器具をバルーン30に張り付ける際に、薬剤付与器具の接着する面またはバルーン30の表面に、接着剤を付着させる。接着剤は、特に限定されないが、液体接着剤であることが好ましく、例えば、シアノアクリレート系の瞬間接着剤、フィブリン接着剤、デンプン系接着剤、天然ゴム系接着剤、セルロース系接着剤、ポリアミド系接着剤等である。これにより、薬剤付与器具に接着層が予め設けられなくても、薬剤付与器具をバルーン30の表面に接着できる。
また、図15に示す第1の変形例のように、接着層13に、接着層13から剥離可能な保護フィルム17が張り付けられてもよい。これにより、使用前の接着層13に、ごみ等が付着することを抑制できる。保護フィルム17は、接着層13をバルーン30に接着する前に、容易に剥がすことができる。また、薬剤層12に、薬剤層12を覆う薬剤保護フィルム18が張り付けられてもよい。薬剤保護フィルム18は、薬剤層12に剥離可能に張り付けられる。または、薬剤保護フィルム18は、水溶性フィルムであってもよい。この場合には、接着層13をバルーン30に接着した後、薬剤層12から薬剤保護フィルム18を除去することなく、バルーン30を血管内に挿入することが可能である。薬剤保護フィルム18を搭載した薬剤転写デバイスを貼り付けられたバルーンカテーテル50は、血管内へ挿入時に、薬剤の脱離を抑制できる。薬剤保護フィルム18の構成材料は、例えば、ゼラチンフィルム、コラーゲンフィルム、デンプンフィルム等である。薬剤保護フィルム18は、生体適合性のある接着剤を介して薬剤層12に張り付けられてもよい。生体適合性のある接着剤は、例えば、シアノアクリレート系、ゼラチン系、フィブリン系等の接着剤である。
また、薬剤層12は、図16(A)に示す第2の変形例のように、シート11(または熱収縮チューブ61)の面に、部分的に配置されてもよい。なお、薬剤層12が設けられる範囲の形状は、特に限定されない。したがって、薬剤付与器具10、60、70は、薬剤層12が設けられる範囲を任意に設定できる。
また、薬剤付与器具10、60、70は、図16(B)に示す第3の変形例のように、複数の孔16を有してもよい。孔16の数や形状は、特に限定されない。
なお、本出願は、2017年11月22日に出願された日本特許出願番号2017-224338号に基づいており、それらの開示内容は、参照され、全体として、組み入れられている。
10、60、70 薬剤付与器具
11 シート
12 薬剤層
13 接着層
14 貫通孔
30 バルーン(医療器具)
61 熱収縮チューブ(シート)
11 シート
12 薬剤層
13 接着層
14 貫通孔
30 バルーン(医療器具)
61 熱収縮チューブ(シート)
Claims (11)
- 生体内に挿入して使用される医療器具に張り付け可能な薬剤付与器具であって、
柔軟なシートと、
前記シートの一方面に設けられる薬剤層と、を有する薬剤付与器具。 - 前記シートの前記薬剤層が設けられる側と反対側の面に設けられる接着層をさらに有する請求項1に記載の薬剤付与器具。
- 前記シートは、筒状であり、前記薬剤層は、前記シートの外周面に設けられる請求項1または2に記載の薬剤付与器具。
- 前記シートは、熱収縮チューブである請求項1~3のいずれか1項に記載の薬剤付与器具。
- 前記接着層は、加熱により接着力を発揮する請求項1~4のいずれか1項に記載の薬剤付与器具。
- 前記医療器具は、拡張および収縮が可能なバルーンである請求項1~5のいずれか1項に記載の薬剤付与器具。
- 前記薬剤層の薬剤は、水不溶性薬剤、水溶性薬剤、親水性ポリマーからなる群から選択される少なくとも1つを含有する請求項1~6のいずれか1項に記載の薬剤付与器具。
- 生体内に挿入して使用される医療器具の表面に薬剤を配置するための薬剤層の形成方法であって、
柔軟なシートの一方面に薬剤層が設けられた薬剤付与器具の前記薬剤層が設けられる側の反対面を、前記医療器具の表面に張り付けるステップを有する薬剤層の形成方法。 - 前記張り付けるステップにおいて、前記シートの前記薬剤層が設けられる側の反対面に設けられる接着層を前記医療器具の表面に接着させる請求項8に記載の薬剤層の形成方法。
- 前記張り付けるステップにおいて、生体内から抜去した医療器具に前記薬剤付与器具を張り付ける請求項8または9に記載の薬剤層の形成方法。
- 前記医療器具は、拡張および収縮が可能なバルーン、ガイドワイヤ、ガイディングシース、ガイディングカテーテルまたはステントである請求項8~10のいずれか1項に記載の薬剤層の形成方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019555364A JP7198218B2 (ja) | 2017-11-22 | 2018-11-22 | 薬剤付与器具および薬剤層の形成方法 |
CN201880075608.7A CN111372645A (zh) | 2017-11-22 | 2018-11-22 | 药物施用器械及药物层的形成方法 |
US16/879,277 US20200282188A1 (en) | 2017-11-22 | 2020-05-20 | Drug layer applying device and method for forming drug layer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-224338 | 2017-11-22 | ||
JP2017224338 | 2017-11-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/879,277 Continuation US20200282188A1 (en) | 2017-11-22 | 2020-05-20 | Drug layer applying device and method for forming drug layer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019103098A1 true WO2019103098A1 (ja) | 2019-05-31 |
Family
ID=66631026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/043180 WO2019103098A1 (ja) | 2017-11-22 | 2018-11-22 | 薬剤付与器具および薬剤層の形成方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20200282188A1 (ja) |
JP (1) | JP7198218B2 (ja) |
CN (1) | CN111372645A (ja) |
WO (1) | WO2019103098A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019103099A1 (ja) | 2017-11-22 | 2019-05-31 | テルモ株式会社 | 薬剤付与デバイスおよび薬剤層の形成方法 |
CN114949551A (zh) * | 2021-06-01 | 2022-08-30 | 深圳市本尚医疗科技有限公司 | 多孔球囊导管系统及其使用方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005000518A (ja) * | 2003-06-13 | 2005-01-06 | National Cardiovascular Center | ステントの製造方法及びステント |
JP2006500996A (ja) * | 2002-09-26 | 2006-01-12 | エンドバスキュラー デバイセス インコーポレイテッド | 溶出性生体適合性移植可能医療器具を介してマイトマイシンを送達するための装置および方法 |
JP2007190369A (ja) * | 2005-12-15 | 2007-08-02 | Cordis Corp | 改善された薬剤放出特性を備えた薬剤溶出物品 |
WO2007148714A1 (ja) * | 2006-06-21 | 2007-12-27 | Kaneka Corporation | リファマイシン誘導体を用いたインプラント |
JP2013223540A (ja) * | 2012-04-19 | 2013-10-31 | Terumo Corp | ステント被覆方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4223061A (en) * | 1977-10-25 | 1980-09-16 | Alza Corporation | Hydrophilic laminate useful for making dispensing device |
JPS5610451A (en) * | 1979-07-05 | 1981-02-02 | Toray Industries | Resin coated metallic plate for vessel |
CN1006714B (zh) * | 1985-09-25 | 1990-02-07 | 庄臣用品公司 | 含有n-乙烯基己内酰胺的热熔粘合剂 |
DE10200388A1 (de) * | 2002-01-08 | 2003-07-24 | Translumina Gmbh | Beschichtungssystem |
CN100507979C (zh) * | 2002-09-10 | 2009-07-01 | 株式会社宝来社 | 具有强贴附力和优良剥离性的标签 |
CA2743022C (en) * | 2007-01-21 | 2012-10-09 | Hemoteq Ag | Methods for coating catheter balloons with a defined quantity of active agent |
US20090192583A1 (en) * | 2008-01-28 | 2009-07-30 | Medtronic Vascular, Inc. | Ordered Coatings for Drug Eluting Stents and Medical Devices |
JP5337478B2 (ja) * | 2008-12-26 | 2013-11-06 | 富士フイルム株式会社 | 鼻腔拡張用補助具 |
WO2012039884A1 (en) * | 2010-09-23 | 2012-03-29 | Boston Scientific Scimed, Inc. | Drug coated balloon with transferable coating |
EP2614810B1 (en) * | 2012-01-16 | 2017-12-06 | Kerr Corporation | Thermoplastic-based polymer adhesive compositions and apparatuses for their use in dental applications |
US20140099351A1 (en) * | 2012-10-04 | 2014-04-10 | Axxia Pharmaceuticals, Llc | Process for making controlled release medical implant products |
US20140371837A1 (en) * | 2013-06-13 | 2014-12-18 | Jung Tang Huang | Drug-eluting sheath |
US9492594B2 (en) * | 2014-07-18 | 2016-11-15 | M.A. Med Alliance SA | Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs |
CN104511084A (zh) * | 2014-12-30 | 2015-04-15 | 深圳市信立泰生物医疗工程有限公司 | 一种球囊导管 |
CN204694872U (zh) * | 2015-06-11 | 2015-10-07 | 丹阳市精通眼镜技术创新服务中心有限公司 | 采用多巴胺作为树脂镜片表面粘接层制作的防雾镜片 |
GB201512030D0 (en) * | 2015-07-09 | 2015-08-19 | Jmedtech Pte Ltd | Composition |
US10695542B2 (en) * | 2016-04-04 | 2020-06-30 | Medtronic Vascular, Inc. | Drug coated balloon |
-
2018
- 2018-11-22 WO PCT/JP2018/043180 patent/WO2019103098A1/ja active Application Filing
- 2018-11-22 JP JP2019555364A patent/JP7198218B2/ja active Active
- 2018-11-22 CN CN201880075608.7A patent/CN111372645A/zh active Pending
-
2020
- 2020-05-20 US US16/879,277 patent/US20200282188A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006500996A (ja) * | 2002-09-26 | 2006-01-12 | エンドバスキュラー デバイセス インコーポレイテッド | 溶出性生体適合性移植可能医療器具を介してマイトマイシンを送達するための装置および方法 |
JP2005000518A (ja) * | 2003-06-13 | 2005-01-06 | National Cardiovascular Center | ステントの製造方法及びステント |
JP2007190369A (ja) * | 2005-12-15 | 2007-08-02 | Cordis Corp | 改善された薬剤放出特性を備えた薬剤溶出物品 |
WO2007148714A1 (ja) * | 2006-06-21 | 2007-12-27 | Kaneka Corporation | リファマイシン誘導体を用いたインプラント |
JP2013223540A (ja) * | 2012-04-19 | 2013-10-31 | Terumo Corp | ステント被覆方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2019103098A1 (ja) | 2020-11-19 |
US20200282188A1 (en) | 2020-09-10 |
CN111372645A (zh) | 2020-07-03 |
JP7198218B2 (ja) | 2022-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2299435T3 (es) | Recubrimientos lubricantes hidrofilos para dispositivos medicos. | |
ES2930181T3 (es) | Tapas amovibles para dispositivos médicos de elución de fármacos | |
EP2766062B1 (en) | Improved formulations for drug-coated medical devices | |
CN102958473A (zh) | 生物体粘附片及片粘附用器件 | |
CN114010917A (zh) | 双药物给药球囊 | |
WO2019103098A1 (ja) | 薬剤付与器具および薬剤層の形成方法 | |
US20200282190A1 (en) | Drug transfer device and method for forming drug layer | |
JPWO2017164281A1 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JPWO2017164280A1 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP2017169740A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP2018068724A (ja) | バルーンカテーテル | |
JP6668131B2 (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
US20120136367A1 (en) | Multi-segment protective sheath for expandable medical devices | |
JP7110230B2 (ja) | 薬剤付与デバイスおよび薬剤層の形成方法 | |
WO2020196230A1 (ja) | バルーンカテーテルおよびバルーン配置方法 | |
JP2017169741A (ja) | バルーンカテーテルおよび処置方法 | |
JP6942593B2 (ja) | 薬剤コート層およびその形成方法 | |
JP2019092811A (ja) | バルーンカテーテル | |
JP7037337B2 (ja) | 薬剤付与デバイスおよび薬剤層の形成方法 | |
JP6697917B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP6914612B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
CN219517553U (zh) | 一种表面覆盖有可降解微针阵列的载药球囊 | |
CN113226430B (zh) | 球囊导管以及球囊配置方法 | |
WO2019059347A1 (ja) | 薬剤コート層およびその形成方法 | |
WO2020196232A1 (ja) | バルーン折りたたみ方法およびバルーン折りたたみ装置並びにバルーンカテーテル |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18880277 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019555364 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18880277 Country of ref document: EP Kind code of ref document: A1 |